PRIMARY STUDY

Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users

Key Findings:  To study the urinary excretion level of 7 different metabolites of ∆9-tetrahydrocannabinol (∆9-THC), subjects were given either oral and vaporized cannabis or a placebo, at differing doses. Results suggest that additional analytes, not just standard ∆9-THC-COOH, may be worth investigating to elucidate better licit versus illicit cannabis consumption.

Type of Study:  Double Blind Clinical Trial

Study Sample Size:  21

Study Result:  Inconclusive

Study Location(s):  United States

Year of Pub:  2022


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinol (CBN), Tetrahydrocannabivarin (THCV), Delta-8-THC

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype I

Dosage: THC low (5–10 mg) THC high (20–25 mg)

Route of Administration:  Inhalation, Oral (Ingestion)



Link to study